Job is a highly versatile tax lawyer with a wealth of domestic and international experience. Job advises on the tax aspects of M&A and real estate transactions, including structuring and negotiating cross-border investments; and regularly works with US and other multinational clients on their European tax issues.

Job van der Pol is a Partner and head of the tax team at Osborne Clarke in the Netherlands. Prior to joining Osborne Clarke, Job was Counsel at Freshfields Bruckhaus Deringer where he worked for more than 13 years.

Job has acted on a number of high-profile tax cases arising from the European Commission’s state aid investigations into tax rulings issued to multi-national companies – both during the investigations and appeals phases. He also assists clients on a wide range of tax related disputes. Job is a member of the Amsterdam Bar and of the Young IFA Netherlands committee.

Job is listed as a “next generation lawyer” by Legal 500, and client feedback includes that Job 'provides very clear and balanced advice' and also 'demonstrates an excellent understanding of the commercial interests involved'.

Job has registered the following principal (and secondary) legal practice areas in the Netherlands Bar’s register of legal practice areas (rechtsgebiedenregister): 

  • Tax law

Based on this registration, he is required to obtain ten training credits per calendar year in each registered principal legal practice area in accordance with the standards set by the Netherlands Bar.

New Babylon complex

Advised Icon Real Estate (Victory advisers) on the tax matters relating to the sale of the New Babylon complex in The Hague to CORESTATE.

Infosys

Advised Infosys on a strategic partnership with ABN AMRO, including the acquisition of a majority-stake in Stater.

CEE Group

Osborne Clarke advises CEE on market entry in the Netherlands.

MediaMonks

Advised MediaMonks on the acquisition of Amsterdam-based film studio Caramel Pictures; world's leading food and liquid's film studio. Read more

Isobionics

Advised on the sale of Isobionics to BASF, read more.